The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Abstract
Selective inhibition of BCL-X L synergizes with docetaxel to inhibit the growth of solid tumors but does not inhibit granulopoiesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“The inability of PZ to efficiently induce Bcl-2 degradation may provide additional advantages for using PROTAC technology to reduce ABT263 on-target toxicity because Bcl-2 inhibition with a high dose or an intensive treatment regimen of ABT263 can lead to neutropenia and lymphocytopenia25.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Self-citationControl of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Self-citationNovack, D. V., Sorenson, C. M., Shutter, J. R., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80065-m · Cited by 1,637
Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,476
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Willis, S. N., Chen, L., Dewson, G., Wei, A. H., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,236
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · cited 5×
“This is in contrast to the single-agent setting, where MTDs of 315 or 325 mg/day were achieved before thrombocytopenia became dose-limiting (11, 31).”
BackgroundMethodResultInfluentialSelf-citationRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855
Basu, A. B., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S. Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.003 · Cited by 828
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734
Self-citationSystematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Criteria for Analyzing Interactions between Biologically Active Agents
Berenbaum, M. C. (1981) · Advances in cancer research · doi:10.1016/s0065-230x(08)60912-4 · Cited by 454
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Self-citationBcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Self-citationNakayama, K., Nakayama, K., Negishi, I., Kuida, K., Sawa, H., & Loh, D. Y. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3700 · Cited by 395
Structure-guided design of a selective BCL-XL inhibitor
Lessène, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 393
Self-citationWang, Z. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00062-e · Cited by 374
Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity
Tao, Z., Hasvold, L. A., Wang, L., Wang, X., Petros, A. M., Park, C. H., Boghaert, E. R., Catron, N. D., Chen, J., Colman, P. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001867 · Cited by 311
Self-citationTahir, S. K., Yang, X., Anderson, M. G., Morgan-Lappe, S. E., Sarthy, A. V., Chen, J., Warner, R. B., Ng, S., Fesik, S. W., Elmore, S. W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2203 · Cited by 308
Self-citationThe Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
Touzeau, C., Dousset, C., Gouill, S. L., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat‐Deceunynck, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.216 · Cited by 290
Self-citationChonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J. A., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B. L., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 276
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, F., Mérino, D., Lee, L., Breslin, K. A., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 275
Kim, L. S., Huang, S., Lu, W., Lev, D. C., & Price, J. E. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000024761.00373.55 · Cited by 210
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M. L., Ferguson, D. C., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4622 · Cited by 209
Self-citationMoore, V. D. G., & Letai, A. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.021 · Cited by 201
Vandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 194
Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Oakes, S. R., Vaillant, F., Lim, E., Lee, L., Breslin, K. A., Feleppa, F., Deb, S., Ritchie, M. E., Takano, E. A., Ward, T. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104778108 · Cited by 194
Villunger, A., Scott, C. L., Bouillet, P., & Strasser, A. (2003) · Blood · doi:10.1182/blood-2002-07-2132 · Cited by 158
Chen, J., Jin, S. S., Abraham, V., Huang, X., Liu, B. A., Mitten, M. J., Nimmer, P. M., Lin, X., Smith, M. L., Shen, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0415 · Cited by 158
Self-citationBogenberger, J. M., Delman, D., Hansen, N., Valdez, R., Fauble, V. D. S., Mesa, R. A., & Tibes, R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.910657 · Cited by 152
Niu, X., Wang, G., Wang, Y., Caldwell, J. T., Edwards, H. J., Xie, C., Taub, J. W., Li, C., Lin, H., & Ge, Y. (2014) · Leukemia · doi:10.1038/leu.2014.72 · Cited by 127
Ackler, S., Mitten, M. J., Foster, K., Oleksijew, A., Refici, M. L., Tahir, S. K., Yu, X. H., Tse, C., Frost, D. J., Fesik, S. W., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1232-1 · Cited by 125
Self-citationZeuner, A., Francescangeli, F., Contavalli, P., Zapparelli, G., Apuzzo, T., Eramo, A., Baiocchi, M., Angelis, M. L. D., Biffoni, M., Sette, G., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.105 · Cited by 116
Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models
Wong, M., Tan, N., Zha, J., Peale, F. V., Jr., Peng, Y., Fairbrother, W. J., & Belmont, L. D. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0693 · Cited by 115
Self-citationNavitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models
Tan, N., Malek, M., Zha, J., Peng, Y., Kassees, R., Berry, L., Fairbrother, W. J., Sampath, D., & Belmont, L. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2353 · Cited by 106
Self-citationKhaw, S. L., Mérino, D., Anderson, M. A., Glaser, S. P., Bouillet, P., Roberts, A. W., & Huang, D. C. S. (2014) · Leukemia · doi:10.1038/leu.2014.1 · Cited by 93
Davids, M. S., Seymour, J. F., Gerecitano, J. F., Kahl, B. S., Pagel, J. M., Wierda, W. G., Anderson, M. A., Rudersdorf, N. K., Gressick, L. A., Montalvo, N. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8522 · Cited by 92
Regulating cell death at, on, and in membranes
Chi, X., Kale, J., Leber, B. F., & Andrews, D. W. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.06.002 · Cited by 75
Olejniczak, E. T., Sant, C. V., Anderson, M. G., Wang, G. G., Tahir, S. K., Sauter, G., Lesniewski, R., & Semizarov, D. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0367 · Cited by 75
Self-citationBcl-xL controls a switch between cell death modes during mitotic arrest
Bah, N. K., Maillet, L., Ryan, J. A., Dubreil, S., Gautier, F., Letai, A. G., Juin, P. P., & Barillé‐Nion, S. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.251 · Cited by 70
Seymour, J. F., Davids, M. S., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Huang, D. C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7015 · Cited by 58
Anderson, N. M., Harrold, I., Mansour, M. R., Sanda, T., McKeown, M. R., Nagykary, N., Bradner, J. E., Zhang, G. L., Look, A. T., & Feng, H. (2013) · Leukemia · doi:10.1038/leu.2013.377 · Cited by 52
Puglisi, M., van Doorn, L., Blanco-Codesido, M., Jonge, M. J. D., Moran, K., Yang, J., Busman, T. A., Franklin, C., Mabry, M., Krivoshik, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2518 · Cited by 24
Assays to Measure p53-Dependent and -Independent Apoptosis
Phillips, D. C., Garrison, S. P., Jeffers, J. R., & Zambetti, G. P. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-017-5_11 · Cited by 14
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,676
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930
Konopleva, M. Y., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L. J., Busman, T. A., McKeegan, E. M., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,101
Self-citation
Metadata
- Authors
- Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., Lowes, K. N., Kovar, P., Chen, J., Jin, S., Smith, M., Xue, J., Zhang, H., Oleksijew, A., Magoc, T. J., Vaidya, K. S., Albert, D. H., Tarrant, J. M., La, N., Wang, L., Tao, Z.-F., Wendt, M. D., Sampath, D., Rosenberg, S. H., Tse, C., S. Huang, D. C., Fairbrother, W. J., Elmore, S. W., & Souers, A. J.
- Affiliations
- AbbVie (United States) (US)
- Genentech (US)
- AbbVie Inc., North Chicago, IL 60064, USA.
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
- Corresponding author
- Leverson, Joel D.
- Ma, Xiaoju Max
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-03-18
- Volume
- 7
- Issue
- 279
- Pages
- 279ra40-279ra40
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2110525250
- Cited by
- 541
- References
- 51
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 34 · 2023: 38 · 2022: 58 · 2021: 56 · 2020: 69 · 2019: 49 · 2018: 58 · 2017: 65 · 2016: 43 · 2015: 12
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Medical Research Council (461219, 461221, 1016701)
- Australian Cancer Research Foundation
- Cancer Council Victoria
- Australian National Health
- Independent Research Institutes Infrastructure Support Scheme (361646)
- Victorian State Government Operational Infrastructure Support
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- BCL-2 inhibitor, venetoclax, navitoclax, BCL-XL inhibition, A-1331852, docetaxel combination, neutropenia, thrombocytopenia, granulopoiesis, solid tumors, chronic lymphocytic leukemia
- MeSH terms
- Docetaxel, Administration, Oral, Aniline Compounds, Animals, Antineoplastic Agents, Cell Survival, Granulocytes, Humans, Isoquinolines, Kinetics, Neoplasm Transplantation, Neoplasms, Neutropenia, Neutrophils, Sulfonamides, Thrombocytopenia, Gene Expression Regulation, Neoplastic, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Gene Expression Profiling, Taxoids, Cell Line, Tumor, bcl-X Protein, Mice, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
